talimogene laherparepvec + ipilimumab

**Talimogene laherparepvec + ipilimumab** is a combination therapy studied for the treatment of unresectable advanced melanoma. - *Talimogene laherparepvec* is an **oncolytic virus therapy** derived from herpes simplex virus type 1, genetically modified to selectively infect and lyse tumor cells and increase local immune activation by expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), thereby improving antigen presentation and T-cell priming. - *Ipilimumab* is a **checkpoint inhibitor**, specifically a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), blocking its inhibitory effect and leading to expansion and activation of anti-tumor T-cells. The rationale for this combination is that talimogene laherparepvec initiates systemic antitumor immune responses, which ipilimumab further augments by relieving T-cell inhibition. This combination demonstrated increased objective response rates versus ipilimumab monotherapy, without additional safety concerns, in patients with advanced melanoma[1][2][3][5].

Other names

T-VEC + ipilimumab